A phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-refractory, metastatic, thyroid carcinoma: Preliminary toxicity and efficacy experience.

@article{Su2006API,
  title={A phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-refractory, metastatic, thyroid carcinoma: Preliminary toxicity and efficacy experience.},
  author={Yungpo Bernard Su and Robert Michael Tuttle and Matthew G. Fury and Ronald A. Ghossein and Bhuvanesh Singh and Katie Herman and Ennapadam S Venkatraman and Hilda E. Stambuk and Richard J. Robbins and David G. Pfister},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={5554}
}
5554 Background: RAI-refractory thyroid cancer carries a poor prognosis, and no effective systemic therapy exists. DEP is a potent histone deacetylase inhibitor with broad in vitro and phase I anti-tumor activity, and has restored sodium-iodide symporter expression and RAI avidity in thyroid cancer cell lines. METHODS Eligible pts have confirmed papillary, follicular, or Hürthle cell carcinoma, progressive measurable disease, and adequate hepatic/renal function. All pts are RAI-refractory by… CONTINUE READING

Similar Papers

Loading similar papers…